Ishares Msci Spain ETF vs Heron Therapeutics Inc — how do they compare? Ishares Msci Spain ETF trades at $57.83 (market cap $2.30B), while Heron Therapeutics Inc trades at $0.36 (market cap $68.01M). The key difference: Ishares Msci Spain ETF is far larger — about 33.8× Heron Therapeutics Inc's market cap, and Ishares Msci Spain ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Spain ETF for 40 Days and Heron Therapeutics Inc for 35 Days on average.
| EWP | HRTX | |
|---|---|---|
Market Cap | $2.30B | $68.01M |
Volume | 845,747 | 1,891,941 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.23 | $1.49 |
52-Week Low | $48.33 | $0.27 |
Typical Hold Time | 40 Days | 35 Days |
Enterprise Value | — | $174.75M |
Signals from Pluang's Aura AI — not financial advice
EWP, the iShares MSCI Spain ETF, trades at $57.82, down 1.73% on the day amid a bearish technical signal. The ETF offers concentrated exposure to Spanish equities with a discounted 16x P/E and 2.7% yield, heavily weighted in financials and utilities. Recent ECB rate hikes to 2.5% and energy-driven inflation pressures create macroeconomic headwinds for European markets.
While EWP provides attractive valuation and yield, the bearish technical outlook and ECB tightening cycle present near-term challenges. The concentrated portfolio in Spanish banks and utilities offers stability but limits diversification. Upside potential depends on Spain's economic resilience amid broader eurozone pressures.
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →